Status:
COMPLETED
JAB-3068 Activity in Adult Patients With Advanced Solid Tumors
Lead Sponsor:
Jacobio Pharmaceuticals Co., Ltd.
Collaborating Sponsors:
AbbVie
Conditions:
Advanced Solid Tumor
Esophageal Squamous Cell Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
To evaluate the safety and tolerability of JAB-3068 administered in investigational regimens in adult participants with advanced solid tumors.
Detailed Description
To assess the safety and tolerability and determine the recommended phase 2 dose (RP2D) of JAB-3068 in combination with PD1 inhibitor in patients with advanced solid tumors.
Eligibility Criteria
Inclusion
- Written informed consent, according to local guidelines, signed and dated by the participant prior to the performance of any study-specific procedures, sampling, or analyses.
- Participant must be ≥18 years of age at the time of signature of the informed consent form (ICF).
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
Exclusion
- History (≤3 years) of cancer that is histologically distinct from the cancers under study, except for cervical carcinoma in situ, superficial non-invasive bladder tumors, or curatively treated Stage I non-melanoma skin cancer
- Known serious allergy to experimental drugs
- Brain or spinal metastases, except if treated by surgery, surgery plus radiotherapy or radiotherapy alone, with no evidence of progression or hemorrhage for ≤21 days before the start of treatment with the study drugs, and has not received any systemic corticosteroids for ≥21 days before the start of treatment with the study drugs
Key Trial Info
Start Date :
April 26 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 29 2023
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT04721223
Start Date
April 26 2021
End Date
December 29 2023
Last Update
September 19 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
2
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
3
Henan Cancer Hospital
Zhengzhou, Henan, China